Mistletoe therapy is gaining increasing attention as a supportive treatment in cancer care, thanks to its potential to boost immunity, alleviate treatment side effects, and improve overall well-being. Originating in Europe, this therapy uses extracts from the mistletoe plant (Viscum album), long valued for its medicinal properties.
ABNOBA GmbH, headquartered in Pforzheim, Germany, is a global leader in mistletoe-based pharmaceuticals. Through ABNOBA India, patients across the country now have access to scientifically developed, high-quality mistletoe preparations designed specifically for integrative cancer treatment.
Unlike conventional cancer treatments that target cancer cells directly, mistletoe therapy focuses on strengthening the body’s defense mechanisms. It is known to stimulate the immune system, promote cellular health, and help reduce the physical toll of chemotherapy and radiation. Many patients experience improved appetite, energy levels, and emotional resilience during treatment.
Mistletoe extracts are typically administered via subcutaneous injections under the guidance of a trained healthcare provider. They are used alongside standard cancer therapies to improve quality of life without interfering with primary treatments.
Research in Germany and other parts of Europe has shown promising results for various cancer types, including breast, ovarian, colorectal, and lung cancers. ABNOBA continues to invest in clinical studies to further validate and expand its therapeutic impact.
As awareness grows in India, mistletoe therapy is emerging as a valuable option within integrative oncology, offering cancer patients a more holistic path to healing.
Learn more at ABNOBA India
